이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Sinopharm Group 대차 대조표 상태
재무 상태 기준 확인 5/6
Sinopharm Group 의 총 주주 지분은 CN¥122.9B 이고 총 부채는 CN¥77.3B, 이는 부채 대 자기자본 비율을 62.9% 로 가져옵니다. 총자산과 총부채는 각각 CN¥413.1B 및 CN¥290.2B 입니다. Sinopharm Group 의 EBIT는 CN¥21.7B 이며 이자보상배율은 10.5 입니다. CN¥48.9B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
78.1%
부채 비율
CN¥95.61b
부채
| 이자 보상 비율 | 11.4x |
| 현금 | CN¥43.33b |
| 주식 | CN¥122.43b |
| 총 부채 | CN¥307.15b |
| 총 자산 | CN¥429.58b |
최근 재무 상태 업데이트
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23
Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Recent updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03재무 상태 분석
단기부채: 1099 의 단기 자산 ( CN¥364.5B )이 단기 부채( CN¥268.0B ).
장기 부채: 1099 의 단기 자산( CN¥364.5B )이 장기 부채( CN¥22.2B ).
부채 대 자본 내역 및 분석
부채 수준: 1099 의 순부채 대 자기자본 비율( 42.7% )은 높음으로 간주됩니다.
부채 감소: 1099 의 부채 대 자기자본 비율은 지난 5년간 97.2% 에서 1.3% 로 감소했습니다.
부채 범위: 1099 의 부채는 영업 현금 흐름 ( 6788.6% )에 의해 잘 충당되었습니다.
이자 보장: 1099 의 부채에 대한 이자 지급은 EBIT( 10.5 x 적용 범위)로 잘 충당됩니다.